Development of formulation for gene therapy utilizing epigenetic effect of HDAC inhibitors

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08035
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Drug development chemistry
• Research Institution: Kansai University
• Principal Investigator: Nagaoka Yasuo 関西大学, 化学生命工学部, 教授 (90243039)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: ヒストン脱アセチル化酵素阻害剤 / HDAC / ナノ粒子 / Vorinostat / SAHA / 遺伝子治療

Outline of Final Research Achievements

Histone deacetylase (HDAC) inhibitors in nature have activity to enhance the gene expression owing to the improvements in the processes of intracellular DNA delivery and intranucleus DNA transcription caused by hyper acetylation of cytosolic microtubules and core histone proteins. We therefore evaluated several types of HDAC inhibitors as enhancer of the gene expression for lipofection. In this study, we developed an efficient formulation for gene therapy in which an HDAC inhibitor, SAHA, is hybridized. The formulation is composed of PEGylated poly-lysine and PEG-SAHA.

Free Research Field

医薬品化学